• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

October 14, 2019
Company Drug/Device Medical Condition Status
Yumanity Therapeutics YTX-7739 Parkinson’s disease Phase 1 trial initiated enrolling 40 healthy subjects
Medivir AB birinapant and radiation therapy Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 1 trial initiated enrolling subjects with recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Debiopharm Debio 1143, with Keytruda (pembrolizumab) Pancreatic and colorectal cancer Phase 1 trial initiated enrolling 46 subjects without other available therapeutic options
City of Hope chimeric antigen receptor (CAR) T cells in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) glioblastoma Phase 1 trial initiated
Hutchinson China MediTech Limited HMPL-523 relapsed or refractory lymphoma Phase 1/1b trial initiated doising subjects with relapsed or refractory lymphoma at sites in the U.S. and Europe
Nektar Therapeutics NKTR-358 (LY3471851) psoriasis Phase 1b trial initiated enrolling 40 subjects with plaque psoriasis
Nektar Therapeutics NKTR-358 (LY3471851) atopic dermatitis Phase 1b trial initiated enrolling 40 subjects with atopic dermatitis
DURECT Corporation DUR-928 non-alcoholic steatohepatitis (NASH) Phase 1b trial initiated enrolling 60 subjects with non-alcoholic steatohepatitis (NASH) with stage 1-3 fibrosis at multiple centers in the U.S.
AVROBIO, Inc. investigational gene therapy cystinosis Phase 1/2 trial initiated four adult subjects and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine at UC San Diego
IDEAYA Biosciences, Inc. cutaneous melanoma harboring a GNAQ or GNA11 (GNAQ/11) mutation solid tumors Phase 1/2 trial initiated
Minoryx Therapeutics MIN-102 Friedreich’s Ataxia Phase 2 trial initiated enrolling 39 subjects ages 12-60 with Friedreich’s Ataxia in four European countries
Oncologie bavituximab in combination with KEYTRUDA (pembrolizumab) gastroesophageal cancer Phase 2 trial initiated enrolling 80 subjects with advanced gastric or gastroesophageal cancer in the U.S., UK, South Korea and Taiwan
Frequency Therapeutics FX-322 Sensorineural Hearing Loss (SNHL) Phase 2a trial initiated enrolling 96 adult subjects ages 18 to 65 with stable SNHL at 12 sites in the U.S.
DURECT Corporation topical DUR-928 mild to moderate plaque psoriasis Phase 2a trial enrolling 20 subjects in the U.S.
Graybug Vision, Inc. GB-102 wet age-related macular degeneration (AMD) Phase 2b trial initiated enrolling 160 subjects with wet AMD at more than 100 sites in the U.S.
iLiAD Biotechnologies, LLC BPZE1 pertussis Phase 2b trial initiated enrolling 300 healthy subjects
Dermira, Inc. lebrikizumab moderate to severe atopic dermatitis Phase 3 trial initiated enrolling 800 adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis at 200 sites in the U.S., Europe and Asia
Galderma nemolizumab moderate to severe atopic dermatitis Phase 3 trial initiated
Seattle Genetics, Inc. tucatinib in combination with ado-trastuzumab emtansine (T-DM1, Kadcyla) breast cancer Phase 3 trial initiated enrolling up to 460 subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Beckman Coulter, Inc. DxA 5000 pre-analytical sample quality detection 510 (k) clearance granted by the FDA
Frequency Therapeutics FX-322 sensorineural hearing loss (SNHL) Fast Track designation granted by the FDA
Novartis Beovu (brolucizumab-dbll) wet age-related macular degeneration (AMD) Approval granted by the FDA
Clinuvel Scenesse (afamelanotide) erythropoietic protoporphyria (EPP) Approval granted by the FDA
Gilead Descovy HIV pre-exposure prophylaxis Approval granted by the FDA
AstraZeneca FASENRA pen (benralizumab) severe eosinophilic asthma Approval granted by the FDA
Galderma AKLIEF (trifarotene) Cream acne Approval granted by the FDA
Octapharma USA WILATE hemophilia A Approval granted by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing